ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Kondrachine AV, Trigg PI, 1997. Global overview of malaria. Indian J Med Res 106:: 39–52.
-
2.
Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI, 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434: 214–217.
-
3.
Nosten F, White NJ, 2007. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 77: 181–192.
-
4.
World Health Organization, 2006. WHO guidelines for the treatment of malaria. Geneva: World Health Organization.
-
5.
Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala MT, Bouchier C, Esterre P, Fandeur T, Mercereau-Puijalon O, 2005. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 366: 1960–1963.
-
6.
Rogers WO, Sem R, Tero T, Chim P, Lim P, Muth S, Socheat D, Ariey F, Wongsrichanalai C, 2009. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar J 8: 10.
-
7.
Ndiaye D, Daily JP, Sarr O, Ndir O, Gaye O, Mboup S, Wirth DF, 2005. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Senegal. Trop Med Int Health 10: 1176–1179.
-
8.
Desjardins RE, Canfield CJ, Haynes JD, Chulay JD, 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother 16: 710–718.
-
9.
Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M, 2004. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother 48: 1803–1806.
-
10.
Baniecki ML, Wirth DF, Clardy J, 2007. High-throughput Plasmodium falciparum growth assay for malaria drug discovery. Antimicrob Agents Chemother 51:: 716–723.
-
11.
Kurth F, Pongratz P, Belard S, Mordmuller B, Kremsner PG, Ramharter M, 2009. In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays. Malar J 8: 79.
-
12.
Pages F, Texier G, Pradines B, Gadiaga L, Machault V, Jarjaval F, Penhoat K, Berger F, Trape JF, Rogier C, Sokhna C, 2008. Malaria transmission in Dakar: a two-year survey. Malar J 7: 178.
-
13.
Menard D, Madji N, Manirakiza A, Djalle D, Koula MR, Talarmin A, 2005. Efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, chloroquine-sulfadoxine-pyrimethamine combination, and amodiaquine-sulfadoxine-pyrimethamine combination in Central African children with noncomplicated malaria. Am J Trop Med Hyg 72: 581–585.
-
14.
Basco LK, Ringwald P, 2001. Analysis of the key pfcrt point mutation and in vitro and in vivo response to chloroquine in Yaounde, Cameroon. J Infect Dis 183: 1828–1831.
-
15.
Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P, 2009. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J 8: 89.
-
16.
Thomas SM, Ndir O, Dieng T, Mboup S, Wypij D, Maguire JH, Wirth DF, 2002. In vitro chloroquine susceptibility and PCR analysis of pfcrt and pfmdr1 polymorphisms in Plasmodium falciparum isolates from Senegal. Am J Trop Med Hyg 66: 474–480.
-
17.
Sarr O, Myrick A, Daily J, Diop BM, Dieng T, Ndir O, Sow PS, Mboup S, Wirth DF, 2005. In vivo and in vitro analysis of chloroquine resistance in Plasmodium falciparum isolates from Senegal. Parasitol Res 97: 136–140.
-
18.
Henry M, Diallo I, Bordes J, Ka S, Pradines B, Diatta B, M’Baye PS, Sane M, Thiam M, Gueye PM, Wade B, Touze JE, Debonne JM, Rogier C, Fusai T, 2006. Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates. Am J Trop Med Hyg 75: 146–151.
-
19.
Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE, Plowe CV, 2003. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 187: 1870–1875.
-
20.
Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV, 2006. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 355: 1959–1966.
-
21.
Brasseur P, Agnamey P, Gaye O, Cisse M, Badiane M, Vaillant M, Taylor WR, Olliaro P, 2009. Dosing accuracy of artesunate and amodiaquine as treatment for falciparum malaria in Casamance, Senegal. Trop Med Int Health 14: 79–87.
-
22.
Wellems TE, Plowe CV, 2001. Chloroquine-resistant malaria. J Infect Dis 184: 770–776.
-
23.
Ekland EH, Fidock DA, 2008. In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes. Int J Parasitol 38: 743–747.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 195 | 166 | 21 |
| Full Text Views | 339 | 10 | 0 |
| PDF Downloads | 100 | 10 | 0 |
A Non-Radioactive DAPI-based High-Throughput In Vitro Assay to Assess Plasmodium falciparum Responsiveness to Antimalarials—Increased Sensitivity of P. falciparum to Chloroquine in Senegal
Daouda Ndiaye
Daouda Ndiaye
Faculty of Medicine and Pharmacy, Cheikh Anta Diop University, Dakar, Senegal; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York
Search for other papers by Daouda Ndiaye in
Current site
Google Scholar
PubMed
Search for other papers by Daouda Ndiaye in
Current site
Google Scholar
PubMed
Vishal Patel
Vishal Patel
Faculty of Medicine and Pharmacy, Cheikh Anta Diop University, Dakar, Senegal; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York
Search for other papers by Vishal Patel in
Current site
Google Scholar
PubMed
Search for other papers by Vishal Patel in
Current site
Google Scholar
PubMed
Allison Demas
Allison Demas
Faculty of Medicine and Pharmacy, Cheikh Anta Diop University, Dakar, Senegal; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York
Search for other papers by Allison Demas in
Current site
Google Scholar
PubMed
Search for other papers by Allison Demas in
Current site
Google Scholar
PubMed
Michele LeRoux
Michele LeRoux
Faculty of Medicine and Pharmacy, Cheikh Anta Diop University, Dakar, Senegal; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York
Search for other papers by Michele LeRoux in
Current site
Google Scholar
PubMed
Search for other papers by Michele LeRoux in
Current site
Google Scholar
PubMed
Omar Ndir
Omar Ndir
Faculty of Medicine and Pharmacy, Cheikh Anta Diop University, Dakar, Senegal; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York
Search for other papers by Omar Ndir in
Current site
Google Scholar
PubMed
Search for other papers by Omar Ndir in
Current site
Google Scholar
PubMed
Souleymane Mboup
Souleymane Mboup
Faculty of Medicine and Pharmacy, Cheikh Anta Diop University, Dakar, Senegal; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York
Search for other papers by Souleymane Mboup in
Current site
Google Scholar
PubMed
Search for other papers by Souleymane Mboup in
Current site
Google Scholar
PubMed
Jon Clardy
Jon Clardy
Faculty of Medicine and Pharmacy, Cheikh Anta Diop University, Dakar, Senegal; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York
Search for other papers by Jon Clardy in
Current site
Google Scholar
PubMed
Search for other papers by Jon Clardy in
Current site
Google Scholar
PubMed
Viswanathan Lakshmanan
Viswanathan Lakshmanan
Faculty of Medicine and Pharmacy, Cheikh Anta Diop University, Dakar, Senegal; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York
Search for other papers by Viswanathan Lakshmanan in
Current site
Google Scholar
PubMed
Search for other papers by Viswanathan Lakshmanan in
Current site
Google Scholar
PubMed
Johanna P. Daily
Johanna P. Daily
Faculty of Medicine and Pharmacy, Cheikh Anta Diop University, Dakar, Senegal; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York
Search for other papers by Johanna P. Daily in
Current site
Google Scholar
PubMed
Search for other papers by Johanna P. Daily in
Current site
Google Scholar
PubMed
Dyann F. Wirth
Dyann F. Wirth
Faculty of Medicine and Pharmacy, Cheikh Anta Diop University, Dakar, Senegal; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York
Search for other papers by Dyann F. Wirth in
Current site
Google Scholar
PubMed
Search for other papers by Dyann F. Wirth in
Current site
Google Scholar
PubMed
The spread of Plasmodium falciparum drug resistance is outpacing new antimalarial development and compromising effective malaria treatment. Combination therapy is widely implemented to prolong the effectiveness of currently approved antimalarials. To maximize utility of available drugs, periodic monitoring of drug efficacy and gathering of accurate information regarding parasite-sensitivity changes are essential. We describe a high-throughput, non-radioactive, field-based assay to evaluate in vitro antimalarial drug sensitivity of P. falciparum isolates from 40 Senegalese patients. Compared with earlier years, we found a significant decrease in chloroquine in vitro and in genotypic resistances (> 50% and > 65%, respectively, in previous studies) with only 23% of isolates showing resistance. This is possibly caused by a withdrawal of chloroquine from Senegal in 2002. We also found a range of artemisinin responses. Prevalence of drug resistance is dynamic and varies by region. Therefore, the implementation of non-radioactive, robust, high-throughput antimalarial sensitivity assays is critical for defining region-specific prophylaxis and treatment guidelines.
Author Notes
Authors' addresses: Daouda Ndiaye, Allison Demas, Omar Ndir, and Souleymane Mboup, Department of Medicine and Pharmacy, Cheikh Anta Diop University, Dakar, Senegal. Vishal Patel and Jon Clardy, Harvard Medical School, Boston, MA. Michele LeRoux and Dyann F. Wirth, Harvard School of Public Health, Boston, MA. Viswanathan Lakshmanan and Johanna P. Daily, Albert Einstein College of Medicine, Bronx, NY.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Kondrachine AV, Trigg PI, 1997. Global overview of malaria. Indian J Med Res 106:: 39–52.
-
2.
Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI, 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434: 214–217.
-
3.
Nosten F, White NJ, 2007. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 77: 181–192.
-
4.
World Health Organization, 2006. WHO guidelines for the treatment of malaria. Geneva: World Health Organization.
-
5.
Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala MT, Bouchier C, Esterre P, Fandeur T, Mercereau-Puijalon O, 2005. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 366: 1960–1963.
-
6.
Rogers WO, Sem R, Tero T, Chim P, Lim P, Muth S, Socheat D, Ariey F, Wongsrichanalai C, 2009. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar J 8: 10.
-
7.
Ndiaye D, Daily JP, Sarr O, Ndir O, Gaye O, Mboup S, Wirth DF, 2005. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Senegal. Trop Med Int Health 10: 1176–1179.
-
8.
Desjardins RE, Canfield CJ, Haynes JD, Chulay JD, 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother 16: 710–718.
-
9.
Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M, 2004. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother 48: 1803–1806.
-
10.
Baniecki ML, Wirth DF, Clardy J, 2007. High-throughput Plasmodium falciparum growth assay for malaria drug discovery. Antimicrob Agents Chemother 51:: 716–723.
-
11.
Kurth F, Pongratz P, Belard S, Mordmuller B, Kremsner PG, Ramharter M, 2009. In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays. Malar J 8: 79.
-
12.
Pages F, Texier G, Pradines B, Gadiaga L, Machault V, Jarjaval F, Penhoat K, Berger F, Trape JF, Rogier C, Sokhna C, 2008. Malaria transmission in Dakar: a two-year survey. Malar J 7: 178.
-
13.
Menard D, Madji N, Manirakiza A, Djalle D, Koula MR, Talarmin A, 2005. Efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, chloroquine-sulfadoxine-pyrimethamine combination, and amodiaquine-sulfadoxine-pyrimethamine combination in Central African children with noncomplicated malaria. Am J Trop Med Hyg 72: 581–585.
-
14.
Basco LK, Ringwald P, 2001. Analysis of the key pfcrt point mutation and in vitro and in vivo response to chloroquine in Yaounde, Cameroon. J Infect Dis 183: 1828–1831.
-
15.
Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P, 2009. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J 8: 89.
-
16.
Thomas SM, Ndir O, Dieng T, Mboup S, Wypij D, Maguire JH, Wirth DF, 2002. In vitro chloroquine susceptibility and PCR analysis of pfcrt and pfmdr1 polymorphisms in Plasmodium falciparum isolates from Senegal. Am J Trop Med Hyg 66: 474–480.
-
17.
Sarr O, Myrick A, Daily J, Diop BM, Dieng T, Ndir O, Sow PS, Mboup S, Wirth DF, 2005. In vivo and in vitro analysis of chloroquine resistance in Plasmodium falciparum isolates from Senegal. Parasitol Res 97: 136–140.
-
18.
Henry M, Diallo I, Bordes J, Ka S, Pradines B, Diatta B, M’Baye PS, Sane M, Thiam M, Gueye PM, Wade B, Touze JE, Debonne JM, Rogier C, Fusai T, 2006. Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates. Am J Trop Med Hyg 75: 146–151.
-
19.
Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE, Plowe CV, 2003. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 187: 1870–1875.
-
20.
Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV, 2006. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 355: 1959–1966.
-
21.
Brasseur P, Agnamey P, Gaye O, Cisse M, Badiane M, Vaillant M, Taylor WR, Olliaro P, 2009. Dosing accuracy of artesunate and amodiaquine as treatment for falciparum malaria in Casamance, Senegal. Trop Med Int Health 14: 79–87.
-
22.
Wellems TE, Plowe CV, 2001. Chloroquine-resistant malaria. J Infect Dis 184: 770–776.
-
23.
Ekland EH, Fidock DA, 2008. In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes. Int J Parasitol 38: 743–747.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 195 | 166 | 21 |
| Full Text Views | 339 | 10 | 0 |
| PDF Downloads | 100 | 10 | 0 |